Gilead extends oncology deal. Gilead Sciences stock loses 1.01 percent.
Published on 10/06/2026 at 17:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences (ISIN US3755581036) agreed with Nurix Therapeutics on October 5, 2026 to extend an oncology research collaboration by two years, according to RTT News. Gilead Sciences stock last stood at EUR 127.62 on Tradegate on October 6, 2026 at 1:51 p.m. CEST, down 1.01 percent from the EUR 128.92 prior close.
Oncology deal adds pipeline depth
The collaboration extension keeps Nurix and Gilead working on an undisclosed oncology program, with the new research term lasting two additional years. The agreement adds a development milestone to a portfolio that Gilead has expanded through oncology acquisitions and drug launches.
The financial impact is not disclosed, so the near-term investment case remains tied more closely to commercial execution than to the collaboration itself. Gilead's second-quarter update showed how that execution is developing across several therapeutic areas.
HIV sales drive the latest outlook
According to Yahoo Finance, Gilead reported second-quarter 2026 HIV sales of USD 5.70 billion, up 12.00 percent year over year. Total product sales reached USD 7.60 billion, up 8.00 percent year over year, while Trodelvy sales rose 26.00 percent to USD 457.00 million.
Management raised full-year 2026 HIV sales growth guidance to 9.00-10.00 percent from 8.00 percent previously. The company also projected total product sales of USD 30.10-30.40 billion, while cell therapy sales were expected to decline by a mid-teens percentage.
Tradegate quote stays below Nasdaq range
The Tradegate substitute quote of EUR 127.62 on October 6, 2026 places the stock below the primary Nasdaq 52-week high of USD 157.29 and above the low of USD 112.82. The currencies and venues are separate, so the Nasdaq range does not measure the euro quote directly.
The primary Nasdaq quote was USD 144.39 at 11:25 a.m. ET on October 6, 2026, with a market capitalization of USD 179.0 billion and volume of 832,606 shares. The company therefore combines a sizeable cash-generating commercial base with continuing exposure to clinical, regulatory and acquisition execution.
Price and investor reference
Gilead Sciences stock was last at EUR 127.62 on Tradegate on October 6, 2026 at 1:51 p.m. CEST, versus the Tradegate prior close of EUR 128.92. The primary Nasdaq quote was USD 144.39 at 11:25 a.m. ET on the same date.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Substitute price Tradegate (as of October 6, 2026, 1:51 p.m. CEST): EUR 127.62
- Change versus Tradegate prior close: minus 1.01 percent
- Tradegate prior close (October 5, 2026): EUR 128.92
- Market capitalization: USD 179.0 billion (as of October 6, 2026)
- 52-week range: USD 112.82-157.29 (as of October 6, 2026)
- Sector / Industry: Health care / Biotechnology
